Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
DSM and JLL form $2-billion pharma services firm by merging DSM Pharmaceutical Products with Patheon
7:57 AM MST | November 19, 2013 | Deepti Ramesh
DSM and JLL Partners (New York), a middle-market private equity firm, will create a new company, which will be a leading, global contract development and manufacturing organization (CDMO) for the pharmaceutical industry and with anticipated sales of about $2 billion in 2014, DSM says. The company will be formed by combining DSM Pharmaceutical Products (Parsippany, NJ), the custom manufacturing and technology business of DSM, with Patheon (Toronto), a portfolio company of JLL. The new company will be 51% owned by JLL and 49% by DSM. The name of the new company...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee